Effect of high or low protamine dosing on postoperative bleeding following heparin anticoagulation in cardiac surgery

Summary

While experimental data state that protamine exerts intrinsic anticoagulation effects, protamine is still frequently overdosed for heparin neutralisation during cardiac surgery with cardiopulmonary bypass (CPB). Since comparative studies are lacking, we assessed the influence of two protamine-to-heparin dosing ratios on perioperative haemostasis and bleeding, and hypothesised that protamine overdosing impairs the coagulation status following cardiac surgery. In this open-label, multicentre, single-blinded, randomised controlled trial, patients undergoing on-pump coronary artery bypass graft surgery were assigned to a low (0.8; n=49) or high (1.3; n=47) protamine-to-heparin dosing group. The primary outcome was 24-hour blood loss. Patient haemostasis was monitored using rotational thromboelastometry and a thrombin generation assay. The low protamine-to-heparin dosing ratio group received less protamine (329 ± 95 vs 539 ± 117 mg; p<0.001), while post-protamine activated clotting times were similar among groups. The high dosing group revealed increased intrinsic clotting times (236 ± 74 vs 196 ± 64 s; p=0.006) and the maximum post-protamine thrombin generation was less suppressed in the low dosing group (38 ± 40% vs 6 ± 9%; p=0.001). Postoperative blood loss was increased in the high dosing ratio group (615 ml; 95% CI 500–830 ml vs 470 ml; 95% CI 420–530 ml; p=0.021) when compared to the low dosing group, respectively. More patients in the high dosing group received fresh frozen plasma (11% vs 0%; p=0.02) and platelet concentrate (21% vs 6%; p=0.04) compared to the low dosing group. Our study confirms in vitro data that abundant protamine dosing is associated with increased postoperative blood loss and higher transfusion rates in cardiac surgery.

Keywords

Heparins - coagulation factors - thrombin - blood products - surgery

• References

• 1 Edmunds jr LH, Colman RW. Thrombin During Cardiopulmonary Bypass. Ann Thorac Surg 2006; 82: 2315-2322.
• 2 Despotis GJ, Avidan MS, Hogue Jr CW. Mechanisms of hemostatic activation during extracorporeal circulation. Ann Thorac Surg 2001; 72: 1821-1831.
• 3 Finley A, Greenberg C.. Heparin sensitivity and resistance: management during cardiopulmonary bypass. Anesth Analg 2013; 116: 1210-22.
• 4 Khan NU, Wayne CK, Barker J. et al. The effects of protamine overdose on coagulation parameters as measured by the thrombelastograph. Eur J Anaesthesiol 2010; 27: 624-627.
• 5 Mittermayr M, Velik-Salchner C, Stalzer B. et al. Detection of protamine and heparin after termination of cardiopulmonary bypass by thrombelastometry (ROTEM): results of a pilot study. Anesth Analg 2009; 108: 743-750.
• 6 Koster A, Börgermann J, Gummert J. et al. Protamine overdose and its impact on coagulation, bleeding, and transfusions after cardiopulmonary bypass: results of a randomised double-blind controlled pilot study. Clin Appl Thromb Hemost 2014; 20: 290-295.
• 7 Cobel-Geard RJ, Hassouna HI. Interaction of protamine sulphate with thrombin. Am J Hematol 1983; 14: 227-233.
• 8 Ni Ainle F, Preston RJ, Jenkins PV. et al. Protamine sulfate down-regulates thrombin generation by inhibiting factor V activation. Blood 2009; 114: 1658-1665.
• 9 Nielsen VG.. Protamine enhances fibrinolysis by decreasing clot strength: role of tissue factor-initiated thrombin generation. Ann Thorac Surg 2006; 81: 1720-1727.
• 10 Shigeta O, Kojima H, Hiramatsu Y. et al. Low-dose protamine based on heparinprotamine titration method reduces platelet dysfunction after cardiopulmonary bypass. J Thorac Cardiovasc Surg 1999; 118: 354-360.
• 11 Mochizuki T, Olson PJ, Szlam F. et al. Protamine reversal of heparin affects platelet aggregation and activated clotting time after cardiopulmonary bypass. Anesth Analg 1998; 87: 781-785.
• 12 Chu AJ, Wang ZG, Raicu M. et al. Protamine inhibits tissue factor-initiated extrinsic coagulation. Br J Haematol 2001; 115: 392-399.
• 13 Khan NU, Wayne CK, Barker J. et al. The effects of protamine overdose on coagulation parameters as measured by the thrombelastograph. Eur J Anaesthesiol 2010; 27: 624-627.
• 14 Berger RL, Ramaswamy K, Ryan TJ.. Reduced protamine dosage for heparin neutralisation in open-heart operations. Circulation 1968; 37 II 154-157.
• 15 Vonk AB, Veerhoek D, van den Brom CE. et al. Individualised heparin and protamine management improves rotational thromboelastometric parameters and postoperative hemostasis in valve surgery. J Cardiothorac Vasc Anesth 2014; 28: 235-241.
• 16 Society of Thoracic Surgeons Blood Conservation Guideline Task Force. Ferraris VA, Brown JR, Despotis GJ. et al. Society of Cardiovascular Anesthesiologists Special Task Force on Blood Transfusion, Shore-Lesserson LJ, Goodnough LT, Mazer CD, et al.; International Consortium for Evidence Based Perfusion, Baker RA, Dickinson TA, FitzGerald DJ, et al. 2011 update to the Society of Thoracic Surgeons and the Society of Cardiovascular Anesthesiologists blood conservation clinical practice guidelines. Ann Thorac Surg 2011; 91: 944-982.
• 17 Kozek-Langenecker SA, Afshari A, Albaladejo P. et al. Management of severe perioperative bleeding: guidelines from the European Society of Anaesthesiology. Eur J Anaesthesiol 2013; 30: 270-382.
• 18 Dunning J, Versteegh M, Fabbri A. et al. EACTS Audit and Guidelines Committee. Guideline on antiplatelet and anticoagulation management in cardiac surgery. Eur J Cardiothorac Surg 2008; 34: 73-92.
• 19 Jobes DR, Aitken GL, Shaffer GW.. Increased accuracy and precision of heparin and protamine dosing reduces blood loss and transfusion in patients undergoing primary cardiac operations. J Thorac Cardiovasc Surg 1995; 110: 36-45.
• 20 Meesters MI, Lancé MD, van der Steeg R. et al. The value of the thromboelastometry heparinase assay (HEPTEM) in cardiac surgery. Thromb Haemost 2015; 114: 1058-1063.
• 21 Hemker HC, Giesen P, Al Dieri R. et al. Calibrated automated thrombin generation measurement in clotting plasma. Pathophysiol Haemost Thromb 2003; 33: 4-15.
• 22 Hemker HC, Béguin S.. Phenotyping the clotting system. Thromb Haemost 2000; 84: 747-751.
• 23 Thompson WH.. Die physiologische Wirkung der Protamine und ihrer Spaltungsprodukte. Hoppe-Seyler Z Physiol Chem 1900; 29: 1.
• 24 Waldschmidt-Leitz E, Stadler P, Steigerwaldt F. Über Blutgerinnung, Hemmung und Beschleunigung. Z physik Chem 1929; 183: 39.
• 25 Chargaff E, Olson KB.. Studies on the chemistry of blood coagulation: VII. Studies on the action of heparin and other anticoagulants: The influence of protamine on the anticoagulant effect in vivo. J Biol Chem 1937; 122: 153-167.
• 26 Balhorn R.. The protamine family of sperm nuclear proteins. Genome Biol 2007; 8: 227.
• 27 Parkin TW, Kvale WF.. Neutralisation of the anticoagulant effects of heparin with protamine (salmine). Am Heart J 1949; 37: 333-342.
• 28 Svenarud P, Øvrum E.. Clinical effects of different protamine doses after cardiopulmonary bypass. Asian Cardiovasc Thorac Ann 2002; 10: 119-123.
• 29 Guo Y, Tang J, Du L. et al. Protamine dosage based on two titrations reduces blood loss after valve replacement surgery: a prospective, double-blinded, randomised study. Can J Cardiol 2012; 28: 547-552.
• 30 Wang J, Ma HP, Zheng H.. Blood loss after cardiopulmonary bypass, standard vs titrated protamine: a meta-analysis. Neth J Med 2013; 71: 123-127.
• 31 Koster A, Fischer T, Praus M. et al. Hemostatic activation and inflammatory response during cardiopulmonary bypass: impact of heparin management. Anesthesiology 2002; 97: 837-841.
• 32 Despotis GJ, Joist JH, Hogue Jr CW. et al. The impact of heparin concentration and activated clotting time monitoring on blood conservation. A prospective, randomised evaluation in patients undergoing cardiac operation. J Thorac Cardiovasc Surg 1995; 110: 46-54.
• 33 Ohata T, Sawa Y, Ohtake S. et al. Clinical role of blood heparin level monitoring during open heart surgery. Jpn J Thorac Cardiovasc Surg 1999; 47: 600-606.
• 34 Keeler JF, Shah MV, Hansbro SD.. Protamine--the need to determine the dose. Comparison of a simple protamine titration method with an empirical dose regimen for reversal of heparinisation following cardiopulmonary bypass. Anaesthesia 1991; 46: 925-928.
• 35 Butterworth J, Lin YA, Prielipp RC. et al. Rapid disappearance of protamine in adults undergoing cardiac operation with cardiopulmonary bypass. Ann Thorac Surg 2002; 74: 1589-1595.
• 36 Murray DJ, Brosnahan WJ, Pennell B. et al. Heparin detection by the activated coagulation time: a comparison of the sensitivity of coagulation tests and heparin assays. J Cardiothorac Vasc Anesth 1997; 11: 24-28.
• 37 Ichikawa J, Kodaka M, Nishiyama K. et al. Reappearance of circulating heparin in whole blood heparin concentration-based management does not correlate with postoperative bleeding after cardiac surgery. J Cardiothorac Vasc Anesth 2014; 28: 1003-1007.
• 38 Schols SE, Lancé MD, Feijge MA. et al. Impaired thrombin generation and fibrin clot formation in patients with dilutional coagulopathy during major surgery. Thromb Haemost 2010; 103: 318-328.
• 39 Portmann AF, Holden WD.. Protamine sulphate, heparin, and blood coagulation. J Clin Invest 1949; 28: 1451-8145.